BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 22172822)

  • 1. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
    Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
    Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
    Legendre C; Brault Y; Morales JM; Oberbauer R; Altieri P; Riad H; Mahony J; Messina M; Pussell B; Martínez JG; Lelong M; Burke JT; Neylan JF;
    Clin Transplant; 2007; 21(3):330-6. PubMed ID: 17488381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.
    Tedesco-Silva H; Garcia VD; Contieri FL; De Boni Monteiro de Carvalho D; Noronha IL; Gonçalves RT; de Paula FJ; Abbud-Filho M; Manfro RC; David-Neto E; Alfieri F; Ikehara E; Jiang Q; Tai SS; Medina-Pestana JO
    Transplant Proc; 2010 Jun; 42(5):1659-66. PubMed ID: 20620495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J; Citterio F; Nanni G; Favi E; Tondolo V; Spagnoletti G; Salerno MP; Castagneto M
    Transplant Proc; 2006 May; 38(4):1034-6. PubMed ID: 16757255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W; Schoenberg L; Lasky RE; Kahan BD
    Transplant Proc; 2007 Dec; 39(10):3086-92. PubMed ID: 18089328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery.
    Hsu HJ; Tian YC; Chen YC; Lai BC; Fang JT; Yang CW; Wu MS
    Ren Fail; 2008; 30(3):303-6. PubMed ID: 18350450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G; Jamieson N; Oberbauer R; Arias M; Murgia MG; Blancho G; Sato R; Stoeckl M; Revicki DA
    Transpl Int; 2007 Oct; 20(10):875-83. PubMed ID: 17854445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to de novo immunosuppression and steroid elimination.
    Lebranchu Y
    Transplant Proc; 2009; 41(6 Suppl):S39-41. PubMed ID: 19651295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.
    Friend P; Russ G; Oberbauer R; Murgia MG; Tufveson G; Chapman J; Blancho G; Mota A; Grandaliano G; Campistol JM; Brault Y; Burke JT;
    Transpl Int; 2007 Sep; 20(9):754-60. PubMed ID: 17565578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M; Scolari MP; Bertoni E; Citterio F; Rigotti P; Cossu M; Dal Canton A; Tisone G; Albertazzi A; Pisani F; Gubbiotti G; Piredda G; Busnach G; Sparacino V; Goepel V; Messa P; Berloco P; Montanaro D; Veroux P; Federico S; Bartezaghi M; Corbetta G; Ponticelli C
    Transplantation; 2009 Nov; 88(10):1194-202. PubMed ID: 19935373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine.
    Castel MA; Farrero M; Vallejos I; Cardona M; Regueiro A; Pérez-Villa F
    Transplant Proc; 2011; 43(6):2244-6. PubMed ID: 21839245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.